CN109476758B - 抗-凝血因子xi抗体 - Google Patents

抗-凝血因子xi抗体 Download PDF

Info

Publication number
CN109476758B
CN109476758B CN201780037421.3A CN201780037421A CN109476758B CN 109476758 B CN109476758 B CN 109476758B CN 201780037421 A CN201780037421 A CN 201780037421A CN 109476758 B CN109476758 B CN 109476758B
Authority
CN
China
Prior art keywords
amino acid
seq
antibody
acid sequence
fxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780037421.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN109476758A (zh
Inventor
Z.陈
K.P.埃尔斯沃尔思
J.米利根
E.奥尔德姆
D.赛菲尔特
V.甘地
M.塔布里兹法
B.普林斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Adimab LLC
Original Assignee
Merck Sharp and Dohme BV
Merck Sharp and Dohme LLC
Adimab LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme BV, Merck Sharp and Dohme LLC, Adimab LLC filed Critical Merck Sharp and Dohme BV
Priority to CN202310501882.9A priority Critical patent/CN116425879A/zh
Publication of CN109476758A publication Critical patent/CN109476758A/zh
Application granted granted Critical
Publication of CN109476758B publication Critical patent/CN109476758B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
CN201780037421.3A 2016-06-14 2017-06-12 抗-凝血因子xi抗体 Active CN109476758B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310501882.9A CN116425879A (zh) 2016-06-14 2017-06-12 抗-凝血因子xi抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349888P 2016-06-14 2016-06-14
US62/349888 2016-06-14
PCT/US2017/036940 WO2017218371A1 (en) 2016-06-14 2017-06-12 Anti-coagulation factor xi antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310501882.9A Division CN116425879A (zh) 2016-06-14 2017-06-12 抗-凝血因子xi抗体

Publications (2)

Publication Number Publication Date
CN109476758A CN109476758A (zh) 2019-03-15
CN109476758B true CN109476758B (zh) 2023-05-23

Family

ID=59078269

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780037421.3A Active CN109476758B (zh) 2016-06-14 2017-06-12 抗-凝血因子xi抗体
CN202310501882.9A Pending CN116425879A (zh) 2016-06-14 2017-06-12 抗-凝血因子xi抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310501882.9A Pending CN116425879A (zh) 2016-06-14 2017-06-12 抗-凝血因子xi抗体

Country Status (29)

Country Link
US (6) US10676536B2 (enExample)
EP (1) EP3469002A1 (enExample)
JP (2) JP7022081B2 (enExample)
KR (2) KR102379580B1 (enExample)
CN (2) CN109476758B (enExample)
AR (1) AR108717A1 (enExample)
AU (3) AU2017286432B2 (enExample)
BR (1) BR112018075858A2 (enExample)
CA (2) CA3172367A1 (enExample)
CL (2) CL2018003565A1 (enExample)
CO (1) CO2018013434A2 (enExample)
CR (1) CR20180583A (enExample)
DO (1) DOP2018000284A (enExample)
EA (1) EA201892716A1 (enExample)
EC (1) ECSP18091593A (enExample)
GE (1) GEP20227382B (enExample)
IL (2) IL315266A (enExample)
JO (1) JOP20180121A1 (enExample)
MA (1) MA45234A (enExample)
MX (2) MX2018015757A (enExample)
MY (1) MY201852A (enExample)
NI (1) NI201800134A (enExample)
PE (1) PE20190416A1 (enExample)
PH (1) PH12018502586A1 (enExample)
SG (2) SG10202103120UA (enExample)
TN (1) TN2018000417A1 (enExample)
TW (2) TWI802193B (enExample)
UA (1) UA129793C2 (enExample)
WO (1) WO2017218371A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2017218371A1 (en) * 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
BR112019012667A2 (pt) 2016-12-23 2020-02-11 Novartis Ag Anticorpos do fator xi e métodos de uso
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
AU2021302202A1 (en) * 2020-07-02 2023-02-16 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-FXI/FXIa antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
KR20230035079A (ko) * 2020-07-03 2023-03-10 수조우 알파맵 씨오., 엘티디. 응고인자 xi(fxi) 결합 단백질
US20240043521A1 (en) 2021-02-09 2024-02-08 Arxx Therapeutics As Anti-S100A4 Humanized Antibodies, Uses and Methods
EP4442273A4 (en) * 2021-11-30 2025-12-24 Suzhou Alphamab Co Ltd METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOEMBOLIC DISEASES
EP4644426A1 (en) * 2022-12-30 2025-11-05 Gan & Lee Pharmaceuticals Co., Ltd. Antibody against coagulation factor xi and/or activated form factor xia thereof, and use thereof
WO2025130748A1 (zh) * 2023-12-22 2025-06-26 四川科伦博泰生物医药股份有限公司 一种抗凝血因子XI/XIa抗体制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104684932A (zh) * 2012-05-10 2015-06-03 拜耳药业股份公司 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
JP2749167B2 (ja) 1988-06-21 1998-05-13 ジェネンテク，インコーポレイテッド 心筋梗塞の処置のための方法および治療用組成物
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH0656382A (ja) 1992-08-04 1994-03-01 Kawasaki Steel Corp コークス乾式消火装置のバケット巻上機の吊ビーム装置
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
JP5198704B2 (ja) 2000-03-03 2013-05-15 メディミューン リミティド エオタキシンに対するヒト抗体及びそれらの使用
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
DK1648509T3 (da) 2003-07-15 2013-01-07 Amgen Inc Humane anti-NGF-neutraliserende antistoffer som selektive NGF-pathway-inhibitorer
AR051805A1 (es) 2004-12-21 2007-02-07 Centocor Inc Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
WO2007067730A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
WO2007067992A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
JP5586952B2 (ja) 2006-06-06 2014-09-10 クルセル ホランド ベー ヴェー 腸球菌に対する殺活性を有するヒトの結合分子及びその使用方法
JP5362563B2 (ja) 2006-08-03 2013-12-11 アストラゼネカ・アクチエボラーグ αＶβ６に対する抗体およびその使用
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2134749B1 (en) 2007-03-22 2013-11-06 The Regents of the University of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3753947A1 (en) 2007-09-14 2020-12-23 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
KR101652125B1 (ko) 2007-09-26 2016-08-29 우드라이 파마 게엠베하 헤파린-결합 표피 성장 인자-유사 성장 인자 항원 결합 단백질
LT3002298T (lt) 2007-11-21 2019-12-10 Univ Oregon Health & Science Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai
AU2016203944A1 (en) 2007-11-21 2016-07-07 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
PL2297207T3 (pl) 2008-06-19 2019-03-29 Prothix Bv Zastosowanie przeciwciał przeciw czynnikowi XI do zapobiegania lub leczenia tworzenia skrzepliny
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
SI2350304T1 (sl) 2008-10-31 2017-04-26 Janssen Biotech, Inc. Antagonisti toll-u podobnega receptorja
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
DK2373691T3 (en) 2008-12-18 2019-04-15 Oregon Health&Science Univ ANTI-FXI ANTIBODIES AND PROCEDURES FOR USE
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
US8734796B2 (en) 2009-03-20 2014-05-27 Amgen Inc. Carrier immunoglobulins
EP2419448A1 (en) 2009-04-16 2012-02-22 Abbott Biotherapeutics Corp. Anti-tnf- antibodies and their uses
CN104558179A (zh) 2009-04-27 2015-04-29 协和发酵麒麟株式会社 用于治疗血液肿瘤的抗IL-3Rα抗体
US8435516B2 (en) 2009-10-12 2013-05-07 Pfizer Inc. Cancer treatment
WO2011056997A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
WO2011079004A1 (en) 2009-12-23 2011-06-30 Schering Corporation Cell line 3m
WO2011097329A2 (en) * 2010-02-03 2011-08-11 Trilogy Ip Holdings, Inc. Mobile communication plan offerings
JP6266343B2 (ja) 2010-07-16 2018-01-24 アディマブ， エルエルシー 抗体ライブラリー
US20120156130A1 (en) 2010-08-06 2012-06-21 Thore Hettmann Use of her3 binding agents in prostate treatment
PH12013500990A1 (en) 2010-11-19 2022-11-23 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
AU2012236068A1 (en) 2011-04-01 2013-10-17 Eureka Therapeutics, Inc. T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
RU2616881C2 (ru) 2011-06-06 2017-04-18 Ново Нордиск А/С Терапевтические антитела
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
ES2588484T3 (es) 2012-04-13 2016-11-03 Rottapharm Biotech S.R.L. Anticuerpo anti-ADAMTS-5, derivados y usos del mismo
JP6441792B2 (ja) 2012-05-17 2018-12-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｇｆｒに結合する抗原結合蛋白質
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP3052523B1 (en) 2013-10-01 2021-03-10 Medimmune Limited Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer
MX2016011885A (es) 2014-03-20 2016-12-02 Japan As Represented By Director-General Of Nat Inst Of Infectious Diseases Anticuerpo con actividad inhibidora de inyeccion frente al virus de hepatitis c.
ES2894867T3 (es) 2014-06-03 2022-02-16 Xbiotech Inc Composiciones y procedimientos de tratamiento y prevención de infecciones por estafilococo áureo
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
MX393951B (es) 2015-04-07 2025-03-24 Alector Llc Anticuerpos antisortilina y métodos para su uso.
HK1252675A1 (zh) 2015-06-12 2019-05-31 Alector Llc 抗cd33抗体及其使用方法
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3325010B1 (en) 2015-07-23 2023-06-21 The Regents of The University of California Antibodies to coagulation factor xia and uses thereof
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
AR107505A1 (es) 2016-01-22 2018-05-09 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulación xi
WO2017218371A1 (en) 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
WO2018054813A1 (en) 2016-09-20 2018-03-29 Bayer Pharma Aktiengesellschaft Novel antibodies against factor xi and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104684932A (zh) * 2012-05-10 2015-06-03 拜耳药业股份公司 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model;Maurits L等;《Thromb Haemost》;20131130;第110卷(第5期);1065-1073 *

Also Published As

Publication number Publication date
UA129793C2 (uk) 2025-08-06
US11661460B2 (en) 2023-05-30
NI201800134A (es) 2019-03-05
US20200270364A1 (en) 2020-08-27
AU2020210233A1 (en) 2020-08-20
AU2017286432A1 (en) 2018-12-06
US20200317811A1 (en) 2020-10-08
US11512142B2 (en) 2022-11-29
IL263272B1 (en) 2025-03-01
NZ786448A (en) 2025-06-27
IL315266A (en) 2024-10-01
AU2024201084A1 (en) 2024-03-14
TW201802120A (zh) 2018-01-16
JP7277500B2 (ja) 2023-05-19
NZ748743A (en) 2025-06-27
MX2018015757A (es) 2019-05-30
DOP2018000284A (es) 2019-01-31
BR112018075858A2 (pt) 2019-04-02
EA201892716A1 (ru) 2019-05-31
MX2023012740A (es) 2024-02-23
MY201852A (en) 2024-03-20
TN2018000417A1 (en) 2020-06-15
CO2018013434A2 (es) 2018-12-28
CN116425879A (zh) 2023-07-14
ECSP18091593A (es) 2019-01-31
NZ786444A (en) 2025-06-27
SG10202103120UA (en) 2021-05-28
PE20190416A1 (es) 2019-03-19
CA3025869A1 (en) 2017-12-21
GEP20227382B (en) 2022-05-25
CA3025869C (en) 2025-10-07
TW202214702A (zh) 2022-04-16
US20170355780A1 (en) 2017-12-14
KR20190018504A (ko) 2019-02-22
US10676536B2 (en) 2020-06-09
US20230287141A1 (en) 2023-09-14
JOP20180121A1 (ar) 2018-12-12
NZ786442A (en) 2025-06-27
PH12018502586A1 (en) 2019-10-07
US11479615B2 (en) 2022-10-25
IL263272A (en) 2018-12-31
CL2018003565A1 (es) 2019-03-22
JP7022081B2 (ja) 2022-02-17
AU2020210233B2 (en) 2024-03-07
CL2024000367A1 (es) 2024-08-23
KR20210021124A (ko) 2021-02-24
WO2017218371A1 (en) 2017-12-21
IL263272B2 (en) 2025-07-01
US11485794B2 (en) 2022-11-01
AU2017286432B2 (en) 2020-09-24
KR102218714B1 (ko) 2021-02-24
JP2019521978A (ja) 2019-08-08
EP3469002A1 (en) 2019-04-17
KR102379580B1 (ko) 2022-03-29
JP2021101720A (ja) 2021-07-15
NZ786443A (en) 2025-06-27
AR108717A1 (es) 2018-09-19
US20200255542A1 (en) 2020-08-13
US20200308302A1 (en) 2020-10-01
CN109476758A (zh) 2019-03-15
NZ786447A (en) 2025-06-27
CR20180583A (es) 2019-07-02
MA45234A (fr) 2019-04-17
TWI802193B (zh) 2023-05-11
SG11201810763TA (en) 2018-12-28
US12275800B2 (en) 2025-04-15
TWI752964B (zh) 2022-01-21
CA3172367A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
JP7366988B2 (ja) 抗凝固因子ｘｉ抗体
US12275800B2 (en) Anti-coagulation factor XI antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220908

Address after: new jersey

Applicant after: MERCK SHARP & DOHME B.V.

Applicant after: ADIMAB, LLC

Address before: new jersey

Applicant before: MERCK SHARP & DOHME Corp.

Applicant before: ADIMAB, LLC

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment